A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a phase 1/2a randomized, double-blind study to evaluate the safety, tolerability,
pharmacokinetics, and pharmacodynamics of study drug AJ201 in subjects with Spinal and Bulbar
Muscular Atrophy (SBMA).